GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Laboratory Corp of America Holdings (NYSE:LH) » Definitions » Equity-to-Asset

Laboratory of America Holdings (Laboratory of America Holdings) Equity-to-Asset

: 0.47 (As of Dec. 2023)
View and export this data going back to 1991. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Laboratory of America Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $7,875 Mil. Laboratory of America Holdings's Total Assets for the quarter that ended in Dec. 2023 was $16,725 Mil. Therefore, Laboratory of America Holdings's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.47.

The historical rank and industry rank for Laboratory of America Holdings's Equity-to-Asset or its related term are showing as below:

LH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35   Med: 0.43   Max: 0.5
Current: 0.47

During the past 13 years, the highest Equity to Asset Ratio of Laboratory of America Holdings was 0.50. The lowest was 0.35. And the median was 0.43.

LH's Equity-to-Asset is ranked worse than
64.85% of 239 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59 vs LH: 0.47

Laboratory of America Holdings Equity-to-Asset Historical Data

The historical data trend for Laboratory of America Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratory of America Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.47 0.50 0.50 0.47

Laboratory of America Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.51 0.50 0.47 0.47

Competitive Comparison

For the Diagnostics & Research subindustry, Laboratory of America Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratory of America Holdings Equity-to-Asset Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Laboratory of America Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Laboratory of America Holdings's Equity-to-Asset falls into.



Laboratory of America Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Laboratory of America Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=7875/16725.1
=0.47

Laboratory of America Holdings's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=7875/16725.1
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratory of America Holdings  (NYSE:LH) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Laboratory of America Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Laboratory of America Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratory of America Holdings (Laboratory of America Holdings) Business Description

Traded in Other Exchanges
Address
358 South Main Street, Burlington, NC, USA, 27215
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Executives
Peter J Wilkinson officer: SVP, Chief Accounting Officer C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Kerrii B Anderson director WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017
Van Der Vaart Sandra D officer: SVP, Global General Counsel 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Paul Rothman director 6 MEADOW ROAD, BALTIMORE MD 21212
Paul R Kirchgraber officer: CEO, Covance Drug Development 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark S Schroeder officer: EVP, President-Diagnostics Lab 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Megan D. Bailey officer: EVP, Chief Strategy Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Jonathan P. Divincenzo officer: EVP, Pres, Central Labs & Intl 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Anita Z Graham officer: EVP, CHRO C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431
Thomas Pike officer: Pres & CEO Clinical Business C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Kirsten Marie Kliphouse director 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg officer: Chief Financial Officer, EVP P O BOX 1017, CHARLOTTE NC 28201-1017
Brian J Caveney officer: SVP, Chief Medical Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215
R Sanders Williams director DUKE UNIVERSITY SCHOOL OF MEDICINE, TRENT DRIVE, DURHAM NC 27706
Amy B. Summy officer: EVP, Chief Marketing Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215